Stemline Therapeutics (NASDAQ: STML) and Juno Therapeutics (NASDAQ:JUNO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.
This is a breakdown of recent ratings and price targets for Stemline Therapeutics and Juno Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Stemline Therapeutics currently has a consensus target price of $33.75, indicating a potential upside of 140.21%. Juno Therapeutics has a consensus target price of $56.21, indicating a potential downside of 35.36%. Given Stemline Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Stemline Therapeutics is more favorable than Juno Therapeutics.
Institutional & Insider Ownership
52.1% of Stemline Therapeutics shares are held by institutional investors. Comparatively, 70.2% of Juno Therapeutics shares are held by institutional investors. 16.7% of Stemline Therapeutics shares are held by insiders. Comparatively, 15.1% of Juno Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Stemline Therapeutics and Juno Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Stemline Therapeutics||$1.04 million||391.37||-$38.30 million||($2.57)||-5.47|
|Juno Therapeutics||$111.87 million||90.26||-$245.58 million||($5.38)||-16.16|
Stemline Therapeutics has higher earnings, but lower revenue than Juno Therapeutics. Juno Therapeutics is trading at a lower price-to-earnings ratio than Stemline Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Stemline Therapeutics and Juno Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Stemline Therapeutics has a beta of -0.07, suggesting that its stock price is 107% less volatile than the S&P 500. Comparatively, Juno Therapeutics has a beta of 3.24, suggesting that its stock price is 224% more volatile than the S&P 500.
Stemline Therapeutics beats Juno Therapeutics on 7 of the 13 factors compared between the two stocks.
About Stemline Therapeutics
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.
About Juno Therapeutics
Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.